MetaCap

Actuate Therapeutics (ACTU) vs Seres Therapeutics (MCRB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Actuate Therapeutics is the larger company by market cap ($13.6 million vs $12.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACTU-68.89%MCRB-54.41%
+4%-35%-74%
Oct 7, 20261 yearNov 20, 2026
ACTU-63.08%MCRB-54.24%
+3%-32%-66%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACTU versus MCRB key metrics
MetricACTUMCRB
Share price$0.2253$1.24
Market cap$13.60M$12.64M
1-day change+5.38%-6.77%
YTD return-96.32%—
1-year return-96.43%—
EPS (TTM)$-0.76$-5.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$789.00K
Net income (latest FY)$-22.23M$5.70M
Operating margin—-11910.14%
Net margin—721.93%
52-week high$7.90$18.86
52-week low$0.174$1.20
Distance from 52-week high-97.15%-93.43%
Analyst consensusnonenone
Avg. price target upside+5084.20%+1270.97%
Average volume807.24K74.83K
Shares outstanding60.38M10.20M
Employees1266
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Actuate Therapeutics

ACTU stock →

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About Seres Therapeutics

MCRB stock →

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.

Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees

ACTU vs MCRB FAQ

Which is bigger, Actuate Therapeutics or Seres Therapeutics?

Actuate Therapeutics (ACTU) is larger, with a market capitalization of $13.60M compared with $12.64M for Seres Therapeutics (MCRB).

Are Actuate Therapeutics and Seres Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons